The 2019 EURETINA Clinical Research Awards have initiated a new funding research Call to support and encourage independent clinical research in the field of retinal medicine. Clinical research, as proposed by clinician or non-clinician researchers, may conduct several types of clinical research, such as observational research studies, register studies (patient or disease registry), natural history / epidemiological studies, phase IV studies (post-authorisation safety studies, “PASS”), genomic research studies, pharmacovigilance studies, retrospective case-control studies, systematic reviews, meta-analyses and several other types of clinical studies. In essence, the proposed clinical research work is designed to focus on “real world” studies, in order to directly benefit patients and to support healthcare across the EU and other jurisdicstions.
The Clinical Research Call for FY2019 aims to fund up to six (6) research projects. The maximum amount that might be awarded to a successful applicant is no more than €300K, always subject to the quality of the research proposal and the benefits for patients. The competition is open to all clinicians and researchers, with EURETINA membership, holding a full time clinical/research post at an EU-based clinical or academic centre (H2020 associated countries). The initiative is available at the following page: https://www.euretina.org/retinal-medicine/.
The purpose of the EURETINA Awards is:
– To support, encourage and fund individuals that actively conduct clinical research in the field of retinal medicine;
– To facilitate and support an independent culture of clinical study for the ultimate benefit of patients with retinal disease;
– To engage and encourage the networking potential of the ophthalmic clinical community across the EU (and H2020 associated countries) to improve both patient care and outcomes.
Funding may be available over 2 years (maximum duration) for the right project with suitable infrastructure and experience. The competition is open to all applicants from the European Union (EU) and several additional countries (designated by H2020 associated countries) who are members of EURETINA. EURETINA looks forward to receiving entries for which the ultimate beneficiary will be the ophthalmic patient and the clinical ophthalmology community.